CAR-T cell therapy for tough juvenile dermatomyositis
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This trial tests a treatment using your own immune cells, modified to target a protein called CD19, for children and teens with juvenile dermatomyositis that hasn't gotten better with standard treatments. The goal is to see if this therapy can help calm the inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 5 and 17 years old.
- You must have been diagnosed with juvenile dermatomyositis based on specific signs like muscle weakness and skin rashes.
- Your disease must be hard to treat: not responding to steroids and at least two other medicines, or affecting organs like lungs, heart, or gut, or causing calcium deposits under skin or muscles, or having repeated rashes or skin ulcers.
- You must test positive for certain myositis-related antibodies (like MDA-5, NXP2, TIF-1γ, Ro-52, or others).
- Your heart, kidneys, liver, and lungs must be working well enough, as checked by tests.
- You cannot have had CAR-T therapy before, and you must not have serious infections, tumors, or other major health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
This trial tests a new type of immune cell therapy (UCAR-T) that targets a protein called CD19 to treat children with a severe form of juvenile dermatomyositis that hasn't responded to standard treatments. It aims to calm the overactive immune system and reduce symptoms like muscle weakness and skin rashes.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells, to reset the immune system in people with severe autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome. It aims to reduce disease activity and potentially improve quality of life.
This trial tests a special type of therapy called CAR-T cells, which are made from the patient's own blood cells and are designed to help control severe autoimmune diseases that haven't improved with other treatments. It is for children and young adults aged 5 to 19 with certain conditions like lupus, scleroderma, or myositis.
Hear when a new Juvenile Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.